Fingerprint
Dive into the research topics of 'U.S. Food and Drug Administration approval: Cabozantinib for the treatment of advanced renal cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
U.S. Food and Drug Administration approval: Cabozantinib for the treatment of advanced renal cell carcinoma
Harpreet Singh, Michael Brave, Julia A. Beaver, Joyce Cheng, Shenghui Tang, Eias Zahalka, Todd R. Palmby, Rajesh Venugopal, Pengfei Song, Qi Liu, Chao Liu, Jingyu Yu, Xiao Hong Chen, Xing Wang, Yaning Wang, Paul G. Kluetz, Selena R. Daniels, Elektra J. Papadopoulos, Rajeshwari Sridhara, Amy E. McKee
Research output: Contribution to journal › Review article › peer-review
28
Scopus
citations